Humana Reaffirms FY2026 Adjusted EPS Guidance of At Least $9, Exceeding Analyst Views
HUM sits 85% above its 52-week low of $163.11.
Summary
Humana reaffirmed its fiscal year 2026 adjusted EPS guidance of at least $9. This guidance is above the current LSEG IBES analyst consensus of $8.81 per share. This follows the company's Q1 earnings report on April 29, which included a downward revision of full-year GAAP EPS guidance, but also strong adjusted EPS. The reaffirmation of adjusted EPS guidance above consensus provides clarity and positive sentiment for investors.
At the time of this announcement, HUM was trading at $301.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $36.7B. The 52-week trading range was $163.11 to $315.66. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.